Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product

Telix Pharmaceuticals Limited is pleased to announce it has entered into an exclusive distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product TLX591-CDx (⁶⁸Ga-PSMA-11), a radiopharmaceutical for the imaging of metastatic prostate cancer.

Under the terms of the agreement, IRE has been appointed as the exclusive commercial distributor of TLX591-CDx in France and French overseas territories, during both the initial period of ‘autorisation d’exploitation temporaire’ (temporary authorisation) and once full European marketing authorisation is granted in 2021.

TLX591-CDx does not have a marketing authorisation in any jurisdiction.

To read full media release please click here.